Friday, November 29, 2019, 11:00 am, IRCM Conference Room, Montpellier
“Current position and prospects for the development of therapeutic monoclonal antibodies in oncology”
Charles Dumontet, Lyon Cancer Research Centre, INSERM U1052, CNRS UMR 5286
Monoclonal antibodies are one of the most rapidly developing families of therapeutic agents in cancer therapy. Since the initial testing and approval of chimeric or humanized antibodies directed against tumor cell antigens, several other types of antibodies have been developed including immunoconjugates, antiangiogenics, bispecifics and immune checkpoint inhibitors. Each of these different types is characterized by specific mechanisms of action. Side-effects also differ according to the nature of the antibody or the target, and may in some cases overlap with those of combined therapies. As the number of validated targets remains very limited, many efforts are currently focused on the identification of novel targets present on tumor cells or in the microenvironment. Immunoconjugate research also involves the improvement of drug-to-antibody ratios as well as evaluation of novel conjugates and immunogenicity. Immune checkpoint inhibitors are used in an increasing number of indications and immune-related side effects are being better diagnoses and treated. Novel immune checkpoints are currently being evaluated. Resistance mechanisms to therapeutic antibodies remain poorly understood, with few preclinical models available and very few studies performed in the clinical setting. Most of the currently available therapeutic antibodies have been approved recently and their use in combination or as single agents will require clinical trials evaluating both anti-tumor efficacy and toxicity endpoints.
Contact: Marie Alix Poul, email@example.com